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Abstract 
Purpose: New treatments with novel mechanisms of action and non‑overlapping toxicities are needed for patients 
with metastatic breast cancer. Etirinotecan pegol (EP) is a long‑acting topoisomerase‑I inhibitor with a unique toxicity 
profile. The randomized phase 3 BEACON study that compared EP to treatment of physician’s choice (TPC) demon‑
strated its clinical activity. We now present detailed safety data from the BEACON trial.
Methods: Patients with locally recurrent or metastatic breast cancer who had received at least two prior cytotoxic 
regimens for advanced disease were randomized to EP or TPC. Prior treatment with an anthracycline, a taxane and 
capecitabine was required. The frequencies of treatment‑emergent AEs (TEAEs) and serious TEAEs were evaluated for 
the safety population, comprising all patients who received at least one dose of assigned treatment.
Results: A total of 831 patients were evaluated (n = 425, EP; n = 406, TPC). Compared with TPC, EP was associated 
with a slightly higher median relative dose intensity (98.3 vs. 92.8 %, respectively) and significantly fewer grade ≥3 
toxicities (48.0 vs. 63.1 %, P < 0.0001). The most commonly reported grade ≥3 toxicities in the EP arm were diarrhea 
(9.6 %) and neutropenia (9.6 %) and in the TPC arm, neutropenia (30.8 %). Median time to onset of grade ≥3 diarrhea 
was delayed with EP relative to TPC (43 vs. 7 days, respectively).
Conclusions: The differentiated mechanism of action of EP resulted in a safety profile that is substantially distin‑
guished from that of current widely used therapies for the treatment of women with advanced breast cancer.
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Background
Chemotherapy prolongs survival and can improve qual-
ity of life (QOL) for patients with metastatic breast can-
cer (MBC) (National Comprehensive Cancer Network 
2015). The use of multiple lines of therapy is limited by 
emergence of resistance and development of cumula-
tive toxicities. As recognized by the American Society of 
Clinical Oncology, tolerability is a critical determinant of 
the clinical value of new cancer drugs (Ellis et al. 2014). 
For this reason, there is a growing need to more closely 
scrutinize the safety profiles of drugs in late stage clinical 
development, particularly when improvements in efficacy 
are relatively modest.
Etirinotecan pegol (EP) is a novel, long-acting topoi-
somerase-1 inhibitor designed to improve the pharma-
cokinetics and tolerability of the prodrug irinotecan. 
Etirinotecan pegol contains a large-chain polyethylene 
glycol (PEG) core and four irinotecan molecules that are 
attached via a cleavable ester-based linker (Hoch et  al. 
2014). Pegylation facilitates accumulation of the molecule 
in tumor tissue through the enhanced permeation and 
retention (EPR) effect, demonstrated in an animal model 
by high and sustained tumor exposure to SN38 after EP 
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administration (Hoch et al. 2014). Slow hydrolysis of the 
linker also alters the pharmacokinetics of irinotecan, 
resulting in prolonged exposure to its active metabolite, 
SN38. The mean half-life of SN38 was extended from 
2  days with conventional irinotecan to 50  days with EP 
in a phase 1 trial (Von Hoff et  al. 2008; Jameson et  al. 
2013). Early clinical studies showed EP to be active and 
generally well tolerated in patients with advanced solid 
tumors, including MBC (Von Hoff et  al. 2008; Jameson 
et  al. 2013; Awada et  al. 2013). A randomized phase 2 
study that assessed two schedules of EP (145 mg/m2 every 
14 or 21  days) in patients with previously treated MBC 
demonstrated considerable antitumor activity (objective 
response rate, 29  %, including two complete responses) 
(Awada et  al. 2013). The every 3-week schedule was 
selected for further clinical development based on the 
clinical data, pharmacokinetics, and tolerability demon-
strated in this trial.
The randomized phase 3 BEACON (BrEAst Cancer 
Outcomes with NKTR-102; registered with ClinicalTri-
als.gov number NCT01492101) study was designed to 
compare the overall survival (OS) of patients with heav-
ily pretreated, locally recurrent, or metastatic breast can-
cer treated with EP given every 3 weeks or a single-agent 
treatment of physician’s choice (TPC), a control arm that 
allowed investigators to choose one of seven commonly 
used cytotoxic drugs (Perez et al. 2015). Median OS was 
numerically longer in the EP arm (12.4 vs. 10.3 months), 
but this difference was not statistically significant [hazard 
ratio (HR), 0.87; 95 % confidence interval (CI) 0.75–1.02; 
P = 0.084]. EP was associated with survival improvements 
(P < 0.05) relative to TPC in important, pre-defined sub-
groups with poor prognoses such as patients with liver 
metastases at baseline (median OS 10.9 vs. 8.3  months, 
respectively; HR 0.73) and those with stable, pre-treated 
brain metastasis at study entry (median OS 10.0 vs. 
4.8 months, respectively; HR 0.51). Adverse event profiles 
differed between treatment arms, with a higher incidence 
of diarrhea reported among EP-treated patients and 
higher rates of neutropenia and neuropathy reported for 
TPC. We now report a more detailed analysis of the safety 
and tolerability of EP relative to TPC from the BEACON 
study.
Methods
BEACON was a randomized, open-label, multicenter, 
phase 3 trial conducted in 11 countries (Perez et al. 2015). 
Briefly, eligible patients were adults with Eastern Cooper-
ative Oncology Group (ECOG) performance status (PS) 
of 0 or 1 for whom single-agent chemotherapy for the 
treatment of locally recurrent or metastatic breast cancer 
was indicated. Eligible patients had received a minimum 
of two prior cytotoxic regimens for advanced disease and 
no more than five for breast cancer in any setting. Prior 
treatment with an anthracycline (unless contraindicated 
or not medically appropriate), a taxane and capecitabine 
was required. Patients with stable brain metastases were 
eligible, provided that local therapy was complete with-
out ongoing need for corticosteroids.
Patients were randomized (1:1) to EP or a control arm 
(TPC) comprising one of seven commercially available 
chemotherapy drugs: eribulin, ixabepilone, vinorelbine, 
gemcitabine, paclitaxel, docetaxel or nab-paclitaxel. Etiri-
notecan pegol was administered at a dose of 145 mg/m2 
every 21  days as a 90-min infusion. TPC was adminis-
tered according to local practice, with the exceptions of 
eribulin and ixabepilone, which were administered in 
accordance with local product labeling.
All adverse events (AEs) were assessed with the 
National Cancer Institute (NCI) Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 4.0. 
For TPC, dose delays, reductions, and discontinuations 
for AEs were made according to the prescribing infor-
mation or local practice guidelines, and supportive care 
was administered at the investigator’s discretion. Dose 
modifications and specific supportive care regimens were 
defined in the protocol for EP. Prior to subsequent cycles, 
patients had to have adequate hematopoietic function; 
full resolution of diarrhea to grade 0 for at least 7  days 
without supportive antidiarrheal measures; and reso-
lution of grade 3 electrolyte abnormalities to grade ≤1. 
Required dose reductions for specific toxicities are listed 
in Table 1; dose re-escalation was not allowed. Treatment 
could be delayed for up to 28 days to allow for recovery 
from toxicity. Patients who required treatment delays 
of >28  days were withdrawn from treatment, unless, in 
the investigator’s opinion and approved by the medical 
monitor, study continuation was deemed of benefit for 
the patient. Loperamide was dispensed to all patients 
randomized to EP at treatment start, with instruction to 
initiate therapy at first onset of diarrhea or loose stool 
and continue until resolution. Prophylactic anti-diar-
rheal medications were prohibited. Other supportive 
care measures were administered at the investigator’s 
discretion.
The frequencies of treatment-emergent AEs (TEAEs) and 
serious TEAEs (TESAEs) were tabulated by MedDRA pre-
ferred term and system organ class and by relationship to 
study drug. Summary statistics were prepared for the safety 
population, which comprises all patients who received 
at least one full or partial dose of assigned treatment. 
The treatment-emergent period was defined as the time 
between the first dose of study drug through 30 days after 
the last dose of study drug or the day prior to initiation of 
subsequent anti-cancer treatment, whichever occurred 
first. A TEAE was defined as an AE that was not present 
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Table 1 Protocol-defined dose modifications for etirinotecan pegol in subsequent cycles based on worst toxicity in prior 
cycle
Adverse event by NCI CTCAE grade Dose modification
Hematologic (thrombocytopenia, anemia, neutropenia, febrile neutropenia)
 Grade 1–2 (except ANC) Maintain dose level
 Grade 2 (ANC <1500/mm3) First occurrence
• Hold until ANC >1500/mm3
• If screening ANC >2000/mm3; restart at reduced dose of 120 mg/m2
• Do not dose reduce if screening ANC was ≥1500 but <2000/mm3
Second occurrence
• Decrease one dose level (to 90 or 120 mg/m2)
Third occurrence
• Discontinue treatment
 Grade 3 (platelets <50 K or Hgb <8 g/dl) First occurrence
• Hold until resolved; restart at 120 mg/m2
Second occurrence
• Decrease additional dose level to 90 mg/m2
Third occurrence
• Discontinue treatment
 Grade 4 (ANC <500/mm3 or platelets <25 K or Hgb <6.5 g/dl) First occurrence
• Hold until resolved (ANC >1500/mm3; Hgb >8 g/dl; platelets >50 K)
• Restart at reduced dose of 120 mg/m2
Second occurrence
• Decrease additional dose level to 90 mg/m2
Third occurrence
• Discontinue treatment
 Febrile neutropenia (grade 3: ANC <1000/mm3 with a single 
temperature >38.3 °C or a sustained temperature  
of ≥38 °C for more than 1 h)
First occurrence
• Hold until resolved until grade 0–1 toxicity
• Restart at reduced dose of 120 mg/m2
Second occurrence
• Decrease additional dose level to 90 mg/m2
Third occurrence
• Discontinue treatment
Diarrhea
 All grades Confirm that diarrhea has been resolved for at least 7 days without use of supportive 
care prior to retreatment
 Grade 1 Maintain dose level; consider prophylactic anti‑diarrheal supportive care
 Grade 2 First occurrence
• Decrease one dose level to 120 mg/m2
• Consider prophylactic anti‑diarrheal supportive care
Second occurrence
• Decrease additional dose level to 90 mg/m2
Third occurrence
• Discontinue treatment
 Grade 3–4 First occurrence:
• Decrease two dose levels to 90 mg/m2
• Use prophylactic anti‑diarrheal supportive care
Second occurrence
• Provided that adequate supportive care was given previously, discontinue treatment
• If the patient did not receive adequate prior supportive care, retreatment may be 
attempted if 2nd episode of grade 3 diarrhea
• Discontinue treatment for 2nd episode of grade 4 diarrhea
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Adverse event by NCI CTCAE grade Dose modification
Dehydration
 Grade 1 • Maintain dose level and consider appropriate prophylactic anti‑emetic or anti‑
diarrheal supportive care
 Grade 2 • Maintain dose level or decrease to 120 mg/m2 after first occurrence; consider appro‑
priate prophylactic anti‑emetic or anti‑diarrheal supportive care
• Decrease one dose level (to 120 or 90 mg/m2) after second occurrence; use appro‑
priate prophylactic anti‑emetic or anti‑diarrheal supportive care
• Up to two dose reductions are allowed
 Grade 3–4 • Delay treatment until resolution to baseline or to grade 0
• Decrease dose level to 90 mg/m2 after first occurrence; use appropriate prophylactic 
anti‑emetic or anti‑diarrheal supportive care
• Discontinue after 2nd occurrence
Nausea/vomiting/abdominal pain
 Grade 1–2 • Maintain dose level and consider prophylactic anti‑emetic supportive care
 Grade 3 • Delay treatment until resolution to baseline or to grade 0
• Decrease one dose level to 120 mg/m2 after first occurrence and use prophylactic 
anti‑emetic supportive care
• Decrease an additional dose level to 90 mg/m2 after second occurrence
• Discontinue treatment after third occurrence
 Grade 4 • Delay treatment until resolution to baseline or to grade 0
• Decrease dose level to 90 mg/m2 after first occurrence and use prophylactic anti‑
emetic supportive care
• Discontinue treatment after second occurrence
Table 1 continued
prior to treatment, but appeared following treatment or 
was present at treatment initiation and worsened during 
treatment. An AE that was present at treatment initiation, 
but resolved and then reappeared while the patient was 
on treatment, was also considered a TEAE, regardless of 
baseline intensity. A TESAE was defined as any untoward 
medical occurrence that, at any dose, resulted in death; was 
life-threatening; required or prolonged a hospitalization; 
resulted in persistent or significant disability or incapacity; 
was a congenital anomaly or birth defect; or was an impor-
tant medical event that, based upon appropriate medical 
judgment, jeopardized the patient and required medical 
or surgical intervention to prevent one of the other out-
comes that comprises an SAE. Odds ratio (OR) and exact 
confidence limits were calculated for AEs that occurred in 
at least 10 % of patients in the safety population. The time 
to onset of events was calculated from the first dose of the 
study treatment. Time to resolution was calculated from 
the onset date to the resolution date, death date, or date of 
start of new anti-cancer therapy. Because incidence rates 
are low in AEs of Special Interest, descriptive statistics were 
summarized based on patients who had the event or who 
had a resolution date when calculating time to onset and 
time to resolution of AEs of Special Interest.
The study was conducted according to the provisions of 
the Declaration of Helsinki and in accordance with Inter-
national Conference on Harmonisation Good Clinical 
Practice standards, US Food and Drug Administration 
regulations, as well as any and all applicable federal, state 
and/or local laws and regulations. All patients gave writ-
ten informed consent, and the study was approved by the 
relevant institutional review board or independent ethics 
committee at each site.
Results
Patients
The results of BEACON have been reported (Perez et al. 
2015). Briefly, 852 patients were randomized and 831 
comprise the safety population (425 treated with EP and 
406 treated with TPC). Eribulin was the most frequently 
selected TPC agent (40 %), followed by vinorelbine (23 %) 
and gemcitabine (18  %). Baseline patient and disease 
characteristics were similar between treatment groups. 
The median age was 55  years in each group. Nearly all 
patients had received a prior anthracycline (96 %), and all 
had received a prior taxane and capecitabine. The median 
number of prior regimens for MBC was three in each 
group.
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Extent of exposure
The overall extent of exposure is summarized in Table 2. 
The median number of cycles was three for both treat-
ment groups, and approximately 25 % of patients in each 
group received six or more cycles. The median duration 
of exposure, calculated between the date of first dose 
and last dose, to EP was 48.0  days (range 1–766  days) 
and 56.5 days for TPC (range 1–607 days). Median rela-
tive dose intensity, calculated as dose intensity divided 
by expected dose intensity, was higher in the EP arm 
(98.3 %) than in the TPC arm (92.8 %). The proportion 
of patients in each arm with any dose reduction, delay, 
or interruption due to AEs appeared similar. The num-
ber of cycles with dose reductions or delays due to AEs 
was lower with EP (11.8 %) than with TPC (19.7 %).
Adverse events
Almost all patients in both treatment arms experienced 
at least one TEAE, and most experienced at least one 
TEAE related to study drug (Table 3). The incidence of 
grade ≥3 TEAEs was significantly higher with TPC than 
EP (63.1 vs. 48.0 %, respectively; OR 0.54; 95 % CI 0.41–
0.71; P  <  0.0001). The most commonly reported grade 
≥3 TEAEs in the EP arm were diarrhea and neutrope-
nia (9.6 % for both). The most commonly reported grade 
≥3 TEAE in the TPC arm was neutropenia (30.8 %). The 
odds of experiencing grade ≥3 neutropenia were sig-
nificantly lower in the EP arm (OR 0.30; 95 % CI 0.21–
0.42). The rates of all other grade ≥3 TEAEs were <5 % 
and generally similar between treatment arms.
Study drug discontinuation due to TEAEs was reported 
for 11.1 and 6.7  % of patients in the EP and TPC arms, 
respectively. There was a higher incidence of diarrhea lead-
ing to discontinuation in the EP arm (3.1 vs. 0 % with TPC) 
and a higher incidence of neuropathy leading to discon-
tinuation in the TPC arm (2.2 vs. 0.2 % with EP). Although 
the rate of grade ≥3 neutropenia was lower in the EP 
arm, a greater proportion of patients were removed from 
EP treatment (2.8  %) for neutropenia compared to TPC 
(0.2 %).
A total of 128 (30.1 %) and 129 (31.8 %) patients in the 
EP and TPC arms experienced 225 and 206 TESAEs, 
respectively. Relatively few of these events were consid-
ered treatment-related (12.2 and 5.9  %, respectively). 
The most commonly reported TESAE in each group was 
pleural effusion (3.5 % for EP; 4.4 % for TPC). The most 
pronounced differences in TESAE rates were for diarrhea 
(4.0 % for EP vs. 0.5 % for TPC) and neutropenia (0.5 % 
for EP vs. 2.5 % for TPC).
Deaths
A total of 327 patients (76.9  %) in the EP arm and 321 
(79.1 %) in the TPC arm died during the study, primarily 
due to progressive disease [312 (73.4 %) and 304 (74.9 %), 
respectively]. Adverse events led to death in five patients 
(1.2 %) in the EP arm and eight (2.0 %) in the TPC arm. 
These events included one case each of pleural effusion, 
respiratory failure, myelodysplastic syndrome, pneumonia, 
and acute renal failure in the EP arm. Fatal events in the 
TPC arm included pleural effusion (n = 2) and one case 
each of respiratory failure, hepatic failure, fluid overload, 
lung infection, neutropenic sepsis, and septic shock.
AEs of special interest
Diarrhea
Nearly two-thirds of EP-treated patients experienced 
diarrhea (Table  4). Most events were grade 1–2 in 
severity, and no patient in either treatment arm experi-
enced grade 4 or 5 diarrhea. The median time to onset 
of grade ≥2 diarrhea in the EP arm was 39.5 days (range 
1–471  days) versus 66.5  days (range 1–385  days) in the 
TPC arm. Median times to onset of grade 3 diarrhea were 
Table 2 Extent of exposure (safety population)
AE adverse event, TPC treatment of physician’s choice
a Calculated as dose intensity divided by expected dose intensity; expected 
dose intensity (mg/m2 per week) equals the assigned dose (mg/m2) divided by 
planned cycle length (days) times 7
b Calculated as total number of dose reductions or delays due to AE divided by 
total of number of cycles received
Endpoint Etirinotecan pegol 
(n = 425)
TPC (n = 406)
Overall exposure  
duration, days
 Median 48.0 56.5
 Mean (SD) 103.0 ± 117.8 99.5 ± 98.3
Cycles completed, n
 Median 3.0 3.0
 Mean (SD) 5.5 ± 5.2 5.0 ± 4.2
Relative dose intensity, %a
 Median 98.3 92.8
 Mean (SD) 92.6 ± 10.7 89.1 ± 16.2
Patient who had any dose 
reduction, n
117 (27.5 %) 115 (28.3 %)
 Due to AE 117 (27.5 %) 108 (26.6 %)
 Other reason(s) 0 (0.0 %) 9 (2.2 %)
Patients who had any dose 
delay, n
178 (41.9 %) 190 (46.8 %)
 Due to AE 151 (35.5 %) 150 (36.9 %)
 Other reason(s) 72 (16.9 %) 88 (21.7)
Patients who had any dose 
interruption, n
18 (4.2 %) 8. (2.0 %)
 Due to AE 15 (3.5 %) 7 (1.7 %)
 Other reason(s) 4 (0.9 %) 1 (0.2 %)
Number of cycles with 
dose reduction or delay 
due to AEb
276 (11.8 %) 397 (19.7 %)
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43 days (range 3–488 days) and 7 days (range 1–79 days), 
respectively.
The median duration of diarrhea of any grade was 
shorter in the EP arm (1.5  days; range 1–52  days) than 
in the TPC arm (3  days; range 1–123  days), while the 
median durations of grade 3 diarrhea were 6 days (range 
1–31  days) and 4  days (range 1–21  days), respectively. 
In the EP arm, 47 patients (11.1 %) had a dose reduction 
and 63 patients (14.8 %) had a dose delay due to diarrhea. 
The corresponding proportions in the TPC treatment 
arm were 0.5 and 0.7 %, respectively. The median EP dose 
delay was 7 days (range 4–35 days). Of the 18 patients in 
the EP arm who permanently discontinued treatment due 
to diarrhea, 15 patients had resolution according to the 
investigator, with a median time to resolution of 28 days 
(range 12–81 days).
Overall, 60.4 % of patients in the EP arm and 12.1 % in 
the TPC arm received concomitant anti-diarrheal medi-
cations, primarily loperamide (58.3 and 6.4 % of patients 
in each respective arm). Additionally, six patients (1.4 %) 
in the EP arm were treated with octreotide, three (0.7 %) 
with tetracosactide, and one each (0.2 %) with lanreotide 
acetate and octreotide acetate.
Neutropenia
The incidence of grade ≥3 neutropenia was higher in the 
TPC arm than in the EP arm (Table 5). The median times 
to onset were 17  days (range 1–225  days) and 62  days 
(range 4–614 days), respectively. The median durations of 
neutropenia were 8 days (range 1–166 days) and 10 days 
(range 2–67  days), respectively. Similar proportions of 
patients experienced a dose reduction due to neutrope-
nia (13.8 % on TPC and 14.4 % on EP), while more in the 
TPC arm experienced a dose delay (20.0 vs. 8.0 %, respec-
tively). The median EP dose delay was 7  days (range 
1–22 days). The median delay could not be calculated for 
the TPC arm because of regimen heterogeneity.
Febrile neutropenia was relatively uncommon, occur-
ring in three (0.7  %) and eight (2.0  %) patients in the 
EP and TPC groups, respectively. Pyrexia was observed 
slightly less frequently in the EP group (7.8 vs. 16.0 %).
Fourteen patients (3.3 %) and seven patients (1.7 %) in 
the EP and TPC arms, respectively, permanently discon-
tinued treatment because of neutropenia. Of these, seven 
and six patients, respectively, had resolution according 
Table 3 Summary of adverse events (safety population)
TEAE treatment emergent adverse event, TESAE treatment emergent serious adverse event, TPC treatment of physician’s choice
a P < 0.0001
b Adverse event which is reported as the primary cause of death of the patient
Endpoint Etirinotecan pegol (n = 425) TPC (n = 406)
Patients with at least 1 TEAE, n 417 (98.1 %) 405 (99.8 %)
Patients with at least 1 grade 3 or higher TEAEa, n 204 (48.0 %) 256 (63.1 %)
Patients with at least 1 TEAE related to study drug, n 394 (92.7 %) 356 (87.7 %)
Patients with at least 1 TEAE leading to study drug discontinuation 47 (11.1 %) 27 (6.7 %)
Patients with AE(s) leading to deathb, n 5 (1.2 %) 8 (2.0 %)
Patients with at least 1 TESAE, n 128 (30.1 %) 129 (31.8 %)
Patients with at least 1 TESAE related to study drug, n 52 (12.2 %) 24 (5.9 %)
Table 4 Onset and resolution of diarrhea
a Patients were counted once within each summary level. If a patient had more 
than one occurrence of the same event, the patient was counted once at the 
highest grade
EP (n = 425) TPC (n = 406)
Number of patients with diarrheaa, n (%) 281 (66.1) 80 (19.7)
 Grade 1 177 (41.6) 52 (12.8)
 Grade 2 63 (14.8) 23 (5.7)
 Grade 3 41 (9.6) 5 (1.2)
Number of patients with diarrhea related 
to study druga, n (%)
268 (63.1) 51 (12.6)
 Grade 1 170 (40.0) 36 (8.9)
 Grade 2 59 (13.9) 11 (2.7)
 Grade 3 39 (9.2) 4 (1.0)
Onset of diarrhea grade 2 or higher, n (%)
 Number of patients 104 28
 ≥60 days 72 (16.9 %) 13 (3.2 %)
 >60–90 days 10 (2.4 %) 8 (2.0 %)
 >90–150 days 11 (2.6 %) 4 (1.0 %)
 >150 days 11 (2.6 %) 3 (0.7 %)
Onset of diarrhea grade 3, n (%)
 Number of patients 41 5
 ≥60 days 25 (5.9 %) 4 (1.0 %)
 >60–90 days 5 (1.2 %) 1 (0.2 %)
 >90–150 days 5 (1.2 %) 0
 >150 days 6 (1.4 %) 0
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to the investigator, at a median time of 35  days (range 
12–82 days) and 12 days (range 10–29 days), respectively.
More than twice as many patients in the TPC arm 
received colony stimulating factors (CSFs; 26.0 % for TPC 
vs. 11.9 % for EP). The most commonly prescribed CSFs 
were filgrastim (18.4  % and 8.9  %, respectively), pegfil-
grastim (7.3 and 3.5 %, respectively), and lenograstim (1.4 
and 0.5 %, respectively).
Neuropathy
The incidence of neuropathy was substantially higher in 
the TPC arm relative to EP (25.6 vs. 7.8 %, respectively), 
as was grade ≥3 neuropathy (3.7 vs. 0.5 %, respectively). 
Neuropathy was the most frequent cause for TPC drug 
discontinuation, occurring in 2.2  % of TPC-treated 
patients (vs. 0.2 % for EP).
Subgroups of interest
Eribulin
The incidence of neutropenia, overall and grade ≥3, 
was higher among eribulin-treated patients than among 
EP-treated patients (Table 6) and time to onset was ear-
lier (median times: 12.0 vs. 62.0 days, respectively). The 
median times to onset of grade ≥3 neutropenia were 16.0 
and 120 days, respectively. Neuropathy, overall and grade 
≥3, was also more commonly reported among eribu-
lin-treated patients (overall: 32.3 vs. 7.8  %, respectively; 
grade ≥3: 4.3 vs. 0.5 %, respectively). The median dura-
tion of neuropathy was longer among eribulin-treated 
patients (22.0 vs. 10.5 days for EP) and more commonly 
associated with dose reductions (9.1 vs. 0.0 % for EP).
Brain metastases
The safety profiles of EP and TPC among patients with 
a history of brain metastases were consistent with the 
overall safety population. More patients in the TPC arm 
experienced at least one grade ≥3 TEAE (70.4 vs. 50  % 
in the EP arm; Table 6). Grade ≥3 diarrhea occurred in 
5.9 and 3.7 % of patients in the EP and TPC arms, respec-
tively, and rates of grade ≥3 neutropenia were 14.7 and 
33.3 %, respectively. Diarrhea was more common in the 
EP arm (55.9 vs. 18.5  % for TPC). Neuropathy-related 
events were more common in the TPC arm (25.6 vs. 
7.8 % for EP).
Discussion
This detailed comparison of the safety and tolerability 
of EP relative to TPC in the randomized phase 3 BEA-
CON study demonstrates that EP is generally well tol-
erated, produces significantly fewer grade 3 and 4 
toxicities, and does not share overlapping toxicities with 
commonly used MBC single-agent therapies, includ-
ing eribulin. Fewer patients in the EP arm experienced 
a dose delay or dose reduction due to AEs, and median 
relative dose intensity was higher than in the TPC arm. 
The development of AEs can limit treatment exposure, 
jeopardize a patient’s likelihood of achieving maxi-
mal therapeutic benefit, and adversely affect QOL. The 
Table 5 Incidence of neutropenia
A composite term encompassing neutropenia, febrile neutropenia, neutropenic 
sepsis, and neutrophil count decreased
EP (n = 425) TPC (n = 406)
Number of patients with neutropenia, 
n (%)
111 (26.1) 174 (43.1)
 Grade 1–2 70 (16.5) 50 (12.3)
 Grade 3 32 (7.5) 79 (19.5)
 Grade 4 9 (2.1) 45 (11.1)
 Grade 5 0 (0) 1 (0.2)
Table 6 Safety profiles in populations of interest
TEAE treatment-emergent adverse event
a Composite term encompassing neutropenia, febrile neutropenia, neutropenic 
sepsis, and neutrophil count decreased
b Composite term encompassing acute polyneuropathy, critical illness 
polyneuropathy, mononeuropathy, mononeuropathy multiplex, multifocal 
motor neuropathy, neuronal neuropathy, neuropathy peripheral, peripheral 
motor neuropathy, peripheral sensorimotor neuropathy, peripheral sensory 
neuropathy, polyneuropathy, polyneuropathy idiopathic progressive, and 
polyneuropathy in malignant disease
c Adverse events reported in 5 % of more of patients in at least one treatment 
arm
Adverse event, n (%) Etirinotecan pegol 
(n = 425) (%)
Eribulin-treated 
patients (n = 164) (%)
Safety among eribulin‑treated patients
 Neutropeniaa, overall 26.1 39.0
 Neutropeniaa, grade 
3 or higher
9.6 32.3
 Neuropathyb, overall 7.8 32.3
 Neuropathyb, grade 3 
or higher
0.5 4.3
Grade 3 or higher TEAE, 
n (%)c
Etirinotecan pegol 
(n = 34)
TPC (n = 27)
Safety among patients with history of brain metastases
 At least one TEAE 17 (50.0) 19 (70.4)
 Nausea 2 (5.9) 0
 Pleural effusion 2 (5.9) 0
 Syncope 2 (5.9) 0
Adverse event, n (%) Etirinotecan pegol 
(n = 425) (%)
Eribulin-treated 
patients (n = 164) (%)
Safety among eribulin‑treated patients
 Diarrhea 2 (5.9) 1 (3.7)
 Neutropenia 5 (14.7) 9 (33.3)
 Hyponatremia 0 2 (7.4)
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relatively favorable tolerability profile of EP in BEACON, 
coupled with statistically superior global health status 
and physical functioning in corresponding QOL analyses, 
is likely to translate into a clinically meaningful benefit 
for heavily pretreated patients with MBC (Cortes et  al. 
2015). In the context of the efficacy seen in the BEACON 
study, especially in certain patient subgroups, these data 
re-inforce the potential utility of EP in the treatment of 
women with MBC.
The safety profile of EP is consistent with expectations 
for a pegylated version of irinotecan. The clinical utility 
of conventional irinotecan is limited by suboptimal phar-
macokinetics. When given intravenously at conventional 
doses, irinotecan produces relatively high peak plasma 
concentrations that are believed to be responsible for 
the cholinergic reactions, significant myelosuppression, 
and early-onset diarrhea seen in clinical practice (Kehrer 
et  al. 2000; Masi et  al. 2004; Takimoto et  al. 2000; Her-
ben et al. 1999). Additionally, the short terminal half-lives 
of the parent compound (9–14 h) and active metabolite 
(24–47  h) result in undetectable plasma levels of these 
cell-cycle specific agents within 1  week of administra-
tion (Kehrer et al. 2000; Chabot 1997; Pitot et al. 2000). A 
21-day dosing interval therefore results in relatively short, 
intermittent tumor exposure to SN38 and peak plasma 
levels associated with toxicity. EP was specifically engi-
neered to produce continuous exposure to SN38 without 
the high peak plasma levels (Hoch et  al. 2014; Jameson 
et  al. 2013). As expected, the incidence of neutropenia 
in BEACON was numerically lower in the EP arm than 
in the TPC arm, and neutropenic events appeared to be 
less severe. Approximately one-quarter of EP-treated 
patients developed neutropenia, and more than half of 
the cases were grade 1–2 in severity. The rates of grade 
3–4 neutropenia were relatively low in the EP arm (9.6 %) 
compared to the TPC arm (30.6  %), and fewer patients 
in the EP arm required growth factor support. A greater 
proportion of EP-treated patients discontinued treatment 
due to neutropenia; there were, however, specific, proto-
col-mandated guidelines for managing neutropenia in the 
EP arm that likely contributed to differential discontinu-
ation rates. Notably, the median time to onset of grade 
3–4 neutropenia was substantially delayed with EP (120 
vs. 16  days for TPC), demonstrating that patients were 
able to receive more courses of EP prior to the develop-
ment of severe neutropenia relative to their counterparts 
in the TPC arm.
Diarrhea is a well-known side effect of irinotecan and, 
as expected, was relatively common among EP-treated 
patients in the BEACON trial. As with neutropenia, the 
time to onset of grade 3–4 diarrhea was longer with EP 
than with TPC. Indeed, this protracted time to diarrhea 
onset is consistent with the pharmacokinetic profile of 
EP, which eliminates the high peak plasma irinotecan 
concentrations associated with early-onset, cholinergic 
diarrhea. Strict protocol-mandated diarrhea manage-
ment guidelines used in BEACON minimized the risk 
for grade ≥3 diarrhea. These guidelines were developed 
based on safety data from phase 2 trials. In a phase 2 
trial initiated without guidelines, the incidence of grade 
3 diarrhea was 23 % in patients with MBC who received 
EP 145 mg/m2 given every 3 weeks (Awada et al. 2013). 
In contrast, fewer than 10  % of EP-treated patients in 
BEACON experienced grade 3 diarrhea, and none expe-
rienced a grade 4 or grade 5 event.
Six of the seven agents comprising the TPC treatment 
options were microtubule inhibitors, including eribulin, 
for which neuropathy is the primary toxicity concern. 
As expected, the incidence of neuropathy, a cumber-
some side effect that interferes significantly with QOL, 
was higher in the TPC arm, and neuropathy was the most 
common cause for TPC drug discontinuation. The lack of 
clinically significant neuropathy with EP therefore pro-
vides an attractive alternative for patients with MBC who 
have experienced or are at increased risk for neuropathy 
in view of prior therapies.
In summary, the BEACON study demonstrated that 
EP produces clinically meaningful outcomes (Perez 
et  al. 2015) with a manageable toxicity profile, result-
ing in an overall favorable risk/benefit ratio for patients 
with heavily pretreated MBC. The lack of substantial 
overlapping toxicities with other agents used in this 
setting suggests that EP could be used sequentially 
with or in lieu of agents with different safety profiles. 
Importantly, the favorable safety profile was maintained 
among patients with a history of brain metastases who 
appeared to gain particular benefit from EP, providing 
further support for on-going clinical development in 
this patient population.
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